| Features | |
| Acne | No |
| Active substance | Etanercept |
| Also known as | TNFR:Fc |
| Aromatization | No |
| Blood pressure | No significant effect |
| Chemical name | Etanercept |
| Dosage (medical) | Typically 50 mg once weekly via subcutaneous injection for adults |
| Dosage (sports) | Not applicable |
| Effects | Reduction of inflammation and immune response modification |
| Formula | C2224H3475N621O701S13 |
| Half-life | Approximately 102 hours |
| HBR | No |
| Hepatotoxicity | No |
| Lab Test | Monitoring of blood counts and liver enzymes |
| Main action | TNF inhibitor |
| Side effects | Infections, injection site reactions, allergic reactions, heart failure, demyelinating disease |
| Storage conditions | Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F) |
| Substance class | Biopharmaceutical, fusion protein |
| Trade name | Enbrel |
| Use in sports | Not typically used in sports |
| WAREHOUSE | International Warehouse 2 |
| Water Retention | No |
| Manufacturer | Pfizer |